Name
Cash Bids
Market Data
News
Ag Commentary
Weather
Resources
|
Is BLDE Stock a Buy as Blade Air Mobility Rebrands?![]() Blade Air Mobility (BLDE), the technology-driven air mobility platform, is set to enter a new chapter as its long-planned legal name change to Strata Critical Medical, takes effect this week. Effective yesterday, Aug. 28, the company will now operate under the new name, signaling a strategic shift toward medical and logistics services. And starting today, Aug. 29, its shares will trade on Nasdaq under the ticker SRTA, with warrants listed as SRTAW. The development follows the completion of the previously announced sale of Blade’s Passenger business to Joby Aviation (JOBY), a transaction valued at up to $125 million and announced on Aug. 4. The news sparked immediate investor enthusiasm, driving the stock up 17.2% on the day of the announcement. With the Passenger segment now divested, Blade Air is positioned to concentrate fully on its healthcare logistics operations, and market watchers are closely monitoring whether the strategic refocus will translate into renewed momentum for the stock. About BLDE/SRTA StockThe New York-based Blade Air Mobility (Strata Critical Medical) offers air transportation and logistics services tailored to hospitals and healthcare providers. With a market cap of roughly $386.4 million, its operations include helicopter and amphibious seaplane flights, nonmedical jet charters, and the transportation of human organs and medical personnel, as well as donor logistics coordination and support services. The stock has performed strongly over the past year, gaining 52% in the last 52 weeks. Momentum remains robust, with a 37.6% increase over six months and a striking 9.7% rise in the past five trading days, underscoring momentum in the wake of strategic developments. From a valuation standpoint, BLDE trades at 1.42 times sales, sitting well below the industry average. This highlights relative attractiveness for potential investors. ![]() Blade Air Surpasses Q2 EarningsBlade Air reported its fiscal second-quarter 2025 results on Aug. 5, which topped Street’s expectations. Total revenue reached $70.8 million, up 4.2% year-over-year (YoY), surpassing analyst estimates of $64.08 million. Growth was led by the Medical segment, which continues to gain traction as hospitals increasingly rely on timely organ transportation and donor coordination. Flight Profit increased 8.5% to $17.7 million, while Medical revenue surged 17.6% to $45.1 million, demonstrating the financial impact of the company’s strategic pivot. Gross profit climbed 13.7% to $12.9 million, while Adjusted EBITDA expanded 233% to $3.2 million, both showing clear operational improvements. Net loss narrowed 67% to $3.7 million, driven by reduced operating losses and increased non-operating income. Net loss per share improved 66.7% to $0.05, beating Wall Street projections. Blade Air ended the quarter with $113.4 million in cash and short-term investments. Furthermore, the company has reaffirmed its full-year guidance, projecting revenue between $245 million and $265 million and targeting double-digit Adjusted EBITDA. On the other hand, analysts anticipate fiscal year 2025 loss per share to narrow 34.6% YoY to $0.17, with further improvement expected in fiscal 2026 as losses could decline another 5.9% to $0.16 per share. What Do Analysts Expect for Blade Air Stock?The stock holds a consensus rating of “Strong Buy” among four analysts covering the stock. Three analysts recommend “Strong Buy,” while one suggests “Hold,” reflecting broad confidence in the company’s strategic focus and operational trajectory. BLDE’s average price target of $5.83 represents potential upside of 23% while the Street-high target of $6.50 reflects a 37% potential gain from current levels. ![]() On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here. |
|